Biomarker

Braintale Cofounders Published the Multicentric Prognosis Clinical Validation of Its BrainScore Coma Solution for Severe Trauma Brain Injuries in Intensive Care Medicine

Retrieved on: 
Thursday, January 20, 2022
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Biomarker, EU, Cardiac arrest, White matter, The Lancet, Patient, Medical device regulation, TBI, Traumatic brain injury, ICU, ISO, CEO, HIV disease progression rates, Medical Device Regulation Act, DTI, Diffusion, Intensive care medicine, Medical device, Caregiver, MRI, Certification, Risk, Neurology, PMID, Intensive Care Medicine (journal), Medical imaging

With a specificity compatible with a personalized decision-making process in ICU, the model successfully identified the patients with favourable and unfavourable outcomes.

Key Points: 
  • With a specificity compatible with a personalized decision-making process in ICU, the model successfully identified the patients with favourable and unfavourable outcomes.
  • This publication strengthens the clinical relevance of Braintale-care platform solutions, bringing personalized decision-making support in the clinic and real-life conditions.
  • it enables better care for severe patients and hard-to-live situations for families while assisting healthcare professionals in their decision-making.
  • Braintale is an innovative company dedicated to deciphering white matter to enable better care in neurology and intensive care with clinically validated prognostic solutions.

Rockley Photonics Reaches Key Milestone in the Development of Cuffless, Non-Invasive Blood Pressure Measurement on the Wrist, Potentially Enabling a New Measurement Technique for Cardiovascular Health

Retrieved on: 
Thursday, January 20, 2022
Software, General Health, Mobile, Wireless, Hardware, Pharmaceutical, Data Management, Consumer Electronics, Technology, Medical Devices, Fitness & Nutrition, Cardiology, Biotechnology, Health, Biomarker, IRB, Forward-looking statement, Wrist, Technology, Patient, WCG, Private Securities Litigation Reform Act, Algorithm, COVID-19, HRV, NYSE, ECG, Calibration, Intellectual property, Solution, Athlete, Health, U.S. Securities and Exchange Commission, PPG, Time, Blood pressure, Goal, Privacy, Artificial intelligence, AI, 100,000, Traction, Contract, Heart rate, Security (finance), LED, Medical imaging, Medical device, Risk management, Rockley

In this pilot study, Rockley researchers have demonstrated that a photonics-based sensor worn on the wrist can measure blood pressure non-invasively.

Key Points: 
  • In this pilot study, Rockley researchers have demonstrated that a photonics-based sensor worn on the wrist can measure blood pressure non-invasively.
  • The Rockley blood pressure sensing device used in the study features a unique laser-based approach and advanced algorithms employing Rockleys cloud and AI capabilities.
  • The signals from the Rockley sensor were shown to provide stronger correlation with the control blood pressure readings from a cuff than standard green-LED PPG signals.
  • Since the announcement, the Rockley sensing platform has continued to gain significant traction in both the consumer and medtech markets.

NanoDx, Inc. Promotes Mike Sampson to Chief Commercial Officer Position

Retrieved on: 
Thursday, January 20, 2022
Biomarker, Sepsis, Patient, Research, Skidmore College, Stroke, TBI, Traumatic brain injury, General manager, COVID-19, Board of directors, MBA, Boston University, View, Marketing, Director, Multimedia, Business operations, Saliva, Inflammation, Blood, Senior, Siemens Healthineers, Board, Medical device, Management, Biochemistry

The company's flagship product, the NanoDx System, is capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen in less than 2 minutes.

Key Points: 
  • The company's flagship product, the NanoDx System, is capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen in less than 2 minutes.
  • NanoDx's platform utilizes a proprietary nanosensor technology with a broad range of potential diagnostic applications including Traumatic Brain Injury (TBI), COVID-19, Influenza, Sepsis and Stroke.
  • Mr. Sampson joined NanoDx in November 2019 as Vice President of Sales.
  • Mr. Sampson began his career in research, manufacturing, and process engineering.

Life Clips’ Subsidiary BelfricsBT Signs MOU With Bluewave International To Explore Blockchain Solutions For Supply Chain Disruption

Retrieved on: 
Thursday, January 20, 2022
Biomarker, Forward-looking statement, Patient, Technology, CBT, Health, Aiki, Cryptocurrency, Private Securities Litigation Reform Act, Psychotherapy, Partnership, IPT, CEO, Government, Solution, Mental health, GLOBE, Blockchain, Movement, Media, OTC Markets Group, Intelligence, Industry, MOU, Founder, Company, Efficiency, Depression, The New York Times, Gartner, Risk, Patent, Compliance, Transport, Investment, Awareness, Apple

Bluewave International is a full-service IT solutions firm specializing in digital advertising, queue management system, web-based application development, and market support systems.

Key Points: 
  • Bluewave International is a full-service IT solutions firm specializing in digital advertising, queue management system, web-based application development, and market support systems.
  • BelfricsBT is the technology division of Belfrics Global, which is a comprehensive blockchain technology solutions company helping businesses bring transparency and decentralization to their operations.
  • BelfricsBT is at the forefront of creating blockchain solutions, while Bluewave International is an industry leader in terms of building customized solutions in various markets.
  • Blockchain possesses the potential of transforming global supply chain management, and Belfrics is planning to take a leading role."

Huma acquires iPLATO Healthcare to advance digital-first delivery of care and remote patient monitoring for NHS patients

Retrieved on: 
Thursday, January 20, 2022
Biomarker, JAMIA, Prescription, Patient, Technology, BD, Degenerative disease, Vital signs, Collection, CEO, Roger Hawkins (drummer), Health care, NHS, Movement, Health, Time, IAPT, Therapy, COVID-19, Depression, Cancer, Pressure, Hospital, MHealth, Medical imaging, Medical device, Pharmaceutical industry

However, remote patient monitoring is still not used widely in primary care.

Key Points: 
  • However, remote patient monitoring is still not used widely in primary care.
  • Dan Vahdat, CEO & Founder of Huma, said: "We are part of the movement using remote patient monitoring and digital biomarkers to transform healthcare.
  • Bringing our patient questionnaires together with Huma's remote patient monitoring capability means that this future is not too far away."
  • We are developing digital biomarkers, predictive algorithms and real-world data from continuous patient monitoring to advance proactive, predictive care.

ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital

Retrieved on: 
Thursday, January 20, 2022
Biotechnology, Networks, Finance, Health, Professional Services, Biomarker, Nanoparticle, Research, Technology, Virology, HQ, LinkedIn, Biology, List of life sciences, Adoption, Seminal vesicles, CEO, Learning, Disease, Solution, University of Oxford, ARCH, Section 32, Drug development, Oxford Nanoimaging, Therapy, Neuroscience, Biomedical Research, Cell biology, McGill University Life Sciences Research Complex, Twist Bioscience, Twitter, Engineering, Life, Founder CEO, Pharmaceutical industry, Management, Medical imaging, Fine chemical, ONI, ARCH Venture Partners, ONI, ARCH VENTURE PARTNERS

The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.

Key Points: 
  • The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.
  • ONIs technology democratizes cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution, said Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners.
  • ARCH Venture Partners invests in advanced technology companies and is one of the worlds leading early-stage technology venture firms.
  • ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

Immunovia appoints Philipp Mathieu as Acting CEO

Retrieved on: 
Thursday, January 20, 2022
Biomarker, Nasdaq Stockholm, CET, LDT, Disease, Department, Pancreatic cancer, Cancer, Lund University, Medical imaging

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET January 20, 2022.
  • The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
  • In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA.

Immunovia appoints Philipp Mathieu as Acting CEO

Retrieved on: 
Thursday, January 20, 2022
Biomarker, Nasdaq Stockholm, CET, LDT, Disease, Department, Pancreatic cancer, Cancer, Lund University, Medical imaging

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET January 20, 2022.
  • The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
  • In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA.

Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Retrieved on: 
Wednesday, January 19, 2022
People, Biomarker, Research, Washington University School of Medicine, Dementia, Tau, Seed, University College London, DIAD, Population, Safety, Domination, BAN2401, Disease, Solution, Parent, Tauopathy, Risk, Alzheimer's disease, Amyloid, Brain, Rapunzel's Tangled Adventure (season 2), Neurology, Amnesia, Amyloid beta, Partnership, Pharmaceutical industry, Medical imaging, Vaccine, Eisai

The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

Key Points: 
  • The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).
  • In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.
  • In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo.

DGAP-News: Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

Retrieved on: 
Wednesday, January 19, 2022
Biomarker, PCR, CRC, Private Securities Litigation Reform Act, SEC, TTS, NASDAQ, Death, U.S. Securities and Exchange Commission, Infection, KSR International Co. v. Teleflex Inc., Cancer, Compliance, Colon, STD, Real-time polymerase chain reaction, Teleflex, Union, COVID-19, Colorectal cancer, Clinical research, American Cancer Society, Company, FDA, Ageing, Forward-looking statement, Patient, FIT, Data management, DNA, Health, Roche Diagnostics, News, Neoplasm, Prospectus, RNA transfection, Trial of the century, Large intestine, BS, AA, Biostatistics, IVDR, DGAP, CRO, Security (finance), Medical device, Vaccine, Pharmaceutical industry, EU, Microbiology, Biology

Under the terms of the engagement, DCN Dx will be responsible for the selection of additional clinical research organizations (CRO) and assist Mainz's management with the development of robust study protocols and associated clinical processes.

Key Points: 
  • Under the terms of the engagement, DCN Dx will be responsible for the selection of additional clinical research organizations (CRO) and assist Mainz's management with the development of robust study protocols and associated clinical processes.
  • Emily brings to the project over 20 years of clinical research experience as a scientist and executive.
  • Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates.
  • DCN Dx provides end-to-end support for rapid diagnostic test development and production in an array of applications.